TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.21
−9.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.24
From 52W high−91.66%
Volume355623.00
Market cap$14.25M
P/E (TTM)—
P/S (TTM)2.0x
Div yield—
Key dataOct 19, 2026
Open
$0.24
From 52W high
−91.66%
Volume
355623.00
Market cap
$14.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
P/E (TTM)
—
RSI (14)
27.1
MomentumView details →
1D Return
−9.00%
YTD Return
−78.21%
SummaryUpdated Jun 1, 2026
TScan Therapeutics, Inc. (NASDAQ:TCRX) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Waltham, Massachusetts. The company went public in July 2021 and focuses on developing innovative T cell receptor-engineered T cell therapies for cancer treatment. TScan operates in the emerging field of cellular immunotherapy, specifically targeting both blood cancers and solid tumors through its proprietary T cell engineering platform.
Similar companies
Latest newsMore news →
TScan Therapeutics appointed R. Keith Woods as chairperson of its Nominating and Corporate Governance Committee.4d agoTScan Therapeutics appointed Stephen Biggar to its Nominating and Corporate Governance Committee.4d agoGabriela Gruia, M.D. resigned from TScan Therapeutics' board of directors.4d ago